06/01/2018 Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine Icon check
05/07/2018 Number of shares and voting rights of ADOCIA as of April, 30 2018 Icon check
05/02/2018 Adocia to hold conference call in regard to the Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China with Tonghua Dongbao Icon check
04/26/2018 Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone®Combo and BioChaperone® Lispro in China. Icon check
04/19/2018 Adocia announces the release of its Reference Document for the year 2017 Icon check
04/16/2018 Number of shares and voting rights of ADOCIA as of March, 31 2018 Icon check
04/16/2018 Adocia initiates First-in-Human Clinical Study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes Icon check
04/16/2018 Adocia announces first quarter 2018 financial results: Cash position and revenue Icon check
04/09/2018 Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon Icon check
03/19/2018 ADOCIA announced its financial results for 2017 and its perspectives for 2018 Icon check
03/06/2018 Number of shares and voting rights of ADOCIA as of February 28, 2018 Icon check
02/17/2018 BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
02/14/2018 BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
02/12/2018 Number of shares and voting rights of ADOCIA as of January 31, 2018 Icon check
02/12/2018 Adocia: additional resources allocated to the liquidity agreement Icon check
02/09/2018 Adocia to Present at the 2018 BIO CEO & Investor Conference in New York Icon check
02/06/2018 Adocia Files Additional Arbitration Claims Against Eli Lilly & Company Icon check
01/25/2018 Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes Icon check
01/10/2018 Number of shares and voting rights of ADOCIA as of December 31, 2017 Icon check
01/08/2018 Adocia announces its financial calendar for 2018 Icon check
01/04/2018 Adocia announces expanded use of BioChaperone® beyond diabetes Icon check
12/07/2017 Number of shares and voting rights of ADOCIA as of November 30, 2017 Icon check
12/06/2017 Adocia announces positive topline study results comparing ultra-rapid insulin BioChaperone® Lispro with Novolog® and Fiasp® in people with type 1 diabetes Icon check
11/20/2017 Adocia Reports Topline Results of BioChaperone® Glucagon Phase 1 Study Icon check
11/20/2017 “Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Excursions vs. Insulin Lispro (LIS) in a 14-Day Treatment Study in Subjects with Type 1 Diabetes (T1DM)” (Poster 964) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
11/08/2017 Number of shares and voting rights of ADOCIA as of October 31, 2017 Icon check
10/20/2017 “Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Control vs. Insulin Lispro (LIS) in a14-Day Treatment Study in Subjects with Type 2 Diabetes (T2DM)” (Poster 994) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
10/12/2017 Number of shares and voting rights of ADOCIA as of September 30, 2017 Icon check
09/20/2017 “Proportional Dose-Exposure Relationship of Ultra-rapid BioChaperone® Lispro (BCLIS) in Healthy Japanese Subjects” (Poster 996), presented by Dr. Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
09/18/2017 Number of shares and voting rights of ADOCIA as of August 31, 2017 Icon check
09/05/2017 Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes Icon check
07/26/2017 Adocia announces appointment of Dr. Stanislav Glezer as Chief Medical Officer Icon check
07/19/2017 Adocia presents first half 2017 financial results Icon check
07/11/2017 Number of shares and voting rights of ADOCIA as of June 30, 2017 Icon check
06/14/2017 Adocia announces financial results for the third quarter 2017
06/09/2017 Number of shares and voting rights of ADOCIA as of May 31, 2017 Icon check
06/09/2017 “Preclinical Efficacy of a Stable Aqueous Formulation of Human Glucagon with BioChaperone® Technology (BC GLU)” (Poster 1150), presented by Dr Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
06/09/2017 “Profil pharmacodynamique de BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, chez des sujets diabétiques de type 2” (Abstract CAD-19), presented by Dr. Martin Gaudier, 2017, Société Francophone du Diabète (France)
06/09/2017 “L’insuline ultra-rapide BioChaperone® Lispro améliore le contrôle glycémique postprandial par rapport à Humalog® chez des sujets diabétiques de type 1” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2017, Société Francophone du Diabète (France)
06/09/2017 “BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, présente un contrôle glycémique amélioré par rapport à un premix d’insuline.” (Abstract CAD-19), presented by Dr. Claire Megret, 2017, Société Francophone du Diabète (France)
06/07/2017 Adocia Initiates a Phase 1b Clinical Study on the Dose-Proportionality of BioChaperone® Combo in People with Type 2 Diabetes Icon check
06/06/2017 Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes Icon check
06/01/2017 Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump Icon check
06/01/2017 Adocia Launches First-in-Man Clinical Study of BioChaperone® Glucagon Icon check
05/30/2017 Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions Icon check
05/30/2017 Adocia to Present at the Jefferies 2017 Global Healthcare Conference in New York Icon check
05/19/2017 Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris Icon check
05/15/2017 Number of shares and voting rights of ADOCIA as of April 30, 2017 Icon check
04/18/2017 Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016 Icon check
04/18/2017 Adocia announces first quarter 2017 financial results Icon check
04/13/2017 Number of shares and voting rights of Adocia as of March 31, 2017 Icon check
03/13/2017 Number of shares and voting rights of ADOCIA as of February 28, 2017 Icon check
03/07/2017 ADOCIA announced its financial results for 2016 and its perspectives for 2017 Icon check
02/14/2017 Adocia announces its revenue and cash position for 2016 Icon check
02/13/2017 Adocia to Present at the Leerink Partners 6th Annual Global Healthcare Conference Icon check
01/27/2017 Adocia to hold conference call on Monday January 30, 2017 Icon check
01/27/2017 Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro Icon check
01/25/2017 Adocia to hold conference call providing an update on its programs Icon check
01/19/2017 Adocia announces the transformation of its business model to increase the value of its projects Icon check
01/06/2017 Half year report on Adocia’s liquidity agreement with Kepler Chevreux
Join our mailing list. Subscribe